Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits

Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity

Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

Health and economic burden of the projected obesity trends in the USA and the UK

Wang, Y. C., McPherson, K., Marsh, T., Gortmaker, S. L., & Brown, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60814-3 · Cited by 2,694 · see citing works

Antipsychotic-induced weight gain: a comprehensive research synthesis

Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · see citing works

Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality

McGrath, J., Saha, S., Chant, D., & Welham, J. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn001 · Cited by 2,280 · see citing works

Prevalence of obesity in the United States, 2009-2010.

Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2012) · PubMed · Cited by 2,070 · see citing works

World Health Report

Prentice, T. (2013) · Res Medica · doi:10.2218/resmedica.v21i1.510 · Cited by 1,710 · see citing works

Abnormalities of the Left Temporal Lobe and Thought Disorder in Schizophrenia

Shenton, M. E., Kikinis, R., Jolesz, F. A., Pollak, S. D., LeMay, M. J., Wible, C. G., Hokama, H., Martin, J., Metcalf, D., Coleman, M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208273270905 · Cited by 1,178 · see citing works

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · see citing works

The economic burden of obesity worldwide: a systematic review of the direct costs of obesity

Withrow, D., & Alter, D. A. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00712.x · Cited by 1,083 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · see citing works

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

Buchanan, R. W., Kreyenbuhl, J. A., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S. S., Fang, B., Peterson, E. L., Aquino, P. R., et al. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 901 · see citing works

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · see citing works

Brain volume in first-episode schizophrenia: Systematic review and meta-analysis of magnetic resonance imaging studies

Steen, R. G., Mull, C., Mcclure, R., Hamer, R. M., & Lieberman, J. A. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.6.510 · Cited by 832 · see citing works

The effect of obesity on health outcomes

Dixon, J. B. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.07.008 · Cited by 797 · see citing works

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · see citing works

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · see citing works

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 679 · see citing works

Brain abnormalities in human obesity: A voxel-based morphometric study

Pannacciulli, N., Del Parigi, A., Chen, K., Le, D. S. N. T., Reiman, E. M., & Tataranni, P. A. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.047 · Cited by 523 · see citing works

Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics

Lindenmayer, J., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.290 · Cited by 465 · see citing works

Severe Mental Illness and Risk of Cardiovascular Disease

Newcomer, J. W., & Hennekens, C. H. (2007) · JAMA · doi:10.1001/jama.298.15.1794 · Cited by 433 · see citing works

Prevalence of obesity in the United States

Baskin, M. L., Ard, J. D., Franklin, F. A., & Allison, D. B. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00165.x · Cited by 410 · see citing works

Brain morphology in first-episode schizophrenia: A meta-analysis of quantitative magnetic resonance imaging studies

Vita, A., Peri, L. M. D., Silenzi, C., & Dieci, M. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.11.004 · Cited by 397 · see citing works

Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: A Randomized Controlled Trial

Wu, R.-R., Zhao, J.-P., Jin, H., Shao, P., Fang, M.-S., Guo, X.-F., He, Y.-Q., Liu, Y.-J., Chen, J.-D., & Li, L.-H. (2008) · JAMA · doi:10.1001/jama.2007.56-b · Cited by 366 · see citing works

Relationship Between Body Mass Index and Gray Matter Volume in 1,428 Healthy Individuals

Taki, Y., Kinomura, S., Sato, K., Inoue, K., Goto, R., Okada, K., Uchida, S., Kawashima, R., & Fukuda, H. (2008) · Obesity · doi:10.1038/oby.2007.4 · Cited by 366 · see citing works

What Happens After the First Episode? A Review of Progressive Brain Changes in Chronically Ill Patients With Schizophrenia

Hulshoff Pol, H. E., & Kahn, R. S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm168 · Cited by 364 · see citing works

Disinhibited Eating in Obese Adolescents Is Associated With Orbitofrontal Volume Reductions and Executive Dysfunction

Maayan, L., Hoogendoorn, C., Sweat, V., & Convit, A. (2011) · Obesity · doi:10.1038/oby.2011.15 · Cited by 345 · see citing works

Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345 · see citing works

GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy

Sharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025269 · Cited by 272 · see citing works

The Genetics of Obesity

Herrera, B. M., & Lindgren, C. M. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0153-z · Cited by 262 · see citing works

Glucagon-like peptide analogues for type 2 diabetes mellitus

Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246 · see citing works

Obesity Is Associated With Reduced White Matter Integrity in Otherwise Healthy Adults*

Stanek, K. M., Grieve, S. M., Brickman, A. M., Korgaonkar, M. S., Paul, R. H., Cohen, R. A., & Gunstad, J. (2010) · Obesity · doi:10.1038/oby.2010.312 · Cited by 231 · see citing works

Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis

Maayan, L. A., Vakhrusheva, J., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.21 · Cited by 230 · see citing works

Elevated BMI Is Associated With Decreased Blood Flow in the Prefrontal Cortex Using SPECT Imaging in Healthy Adults

Willeumier, K. C., Taylor, D. V., & Amen, D. G. (2011) · Obesity · doi:10.1038/oby.2011.16 · Cited by 223 · see citing works

Alterations of the brain reward system in antipsychotic naïve schizophrenia patients.

Nielsen, M., Rostrup, E., Wulff, S., Bak, N., Lublin, H., Kapur, S., & Glenthøj, B. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.007 · Cited by 222 · see citing works

Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006

Hoang, U., Stewart, R., & Goldacre, M. J. (2011) · BMJ · doi:10.1136/bmj.d5422 · Cited by 222 · see citing works

Relationship between body mass index and brain volume in healthy adults

Gunstad, J., Paul, R. H., Cohen, R. A., Tate, D. F., Spitznagel, M. B., Grieve, S., & Gordon, E. (2008) · International Journal of Neuroscience · doi:10.1080/00207450701392282 · Cited by 216 · see citing works

Long-term effects of a very low-carbohydrate diet and a low-fat diet on mood and cognitive function

Brinkworth, G. D. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.329 · Cited by 205 · see citing works

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

Mells, J. E., Fu, P. P., Sharma, S., Olson, D., Cheng, L., Handy, J. A., Saxena, N. K., Sorescu, D., & Anania, F. A. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00274.2011 · Cited by 202 · see citing works

Intentional weight loss in overweight and obese individuals and cognitive function: a systematic review and meta‐analysis

Siervo, M., Arnold, R. J., Wells, J. C. K., Tagliabue, A., Colantuoni, A., Albanese, E., Brayne, C., & Stephan, B. C. M. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00903.x · Cited by 198 · see citing works

The stigma of obesity in the general public and its implications for public health - a systematic review

Sikorski, C., Luppa, M., Kaiser, M., Glaesmer, H., Schomerus, G., König, H., & Riedel-Heller, S. G. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-661 · Cited by 196 · see citing works

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

McClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193 · see citing works

Body mass index and magnetic resonance markers of brain integrity in adults

Gazdzinski, S., Kornak, J., Weiner, M. W., & Meyerhoff, D. J. (2008) · Annals of Neurology · doi:10.1002/ana.21377 · Cited by 191 · see citing works

Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease

Martin, B., Golden, E., Carlson, O. D., Pistell, P. J., Zhou, J., Kim, W., Frank, B. P., Thomas, S., Chadwick, W., Greig, N. H., et al. (2008) · Diabetes · doi:10.2337/db08-0799 · Cited by 181 · see citing works

Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state

Benetti, S., Mechelli, A., Picchioni, M., Broome, M. R., Williams, S., & McGuire, P. K. (2009) · Brain · doi:10.1093/brain/awp098 · Cited by 181 · see citing works

Prevalence of Obesity in Sweden

Neovius, M., Janson, A., & Rössner, S. (2006) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00190.x · Cited by 172 · see citing works

Nutritional Intervention to Prevent Weight Gain in Patients Commenced on Olanzapine: A Randomizedcontrolled Trial

Evans, S. M., Newton, R., & Higgins, S. (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01607.x · Cited by 158 · see citing works

Diffusion tensor imaging in schizophrenia

Kyriakopoulos, M., Bargiotas, T., Barker, G. J., & Frangou, S. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2007.12.004 · Cited by 153 · see citing works

Neuroprotective properties of GLP-1: theoretical and practical applications

Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 152 · see citing works

Gut hormones: Implications for the treatment of obesity

Neary, M. T., & Batterham, R. L. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.005 · Cited by 138 · see citing works

Variability in Reward Responsivity and Obesity: Evidence from Brain Imaging Studies

Burger, K. S., & Stice, E. M. (2011) · Current Drug Abuse Reviews · doi:10.2174/1874473711104030182 · Cited by 138 · see citing works

Diabetes medications and body weight

Mitri, J., & Hamdy, O. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903081725 · Cited by 136 · see citing works

Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRI

Pinkham, A. E., Loughead, J., Ruparel, K., Wu, W., Overton, E. E., Gur, R. E., & Gur, R. C. (2011) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2011.06.013 · Cited by 130 · see citing works

At-Risk Variant in TCF7L2 for Type II Diabetes Increases Risk of Schizophrenia

Hansen, T. F., Ingason, A., Djurovic, S., Melle, I. S., Fenger, M., Gústafsson, Ó., Jakobsen, K. D., Rasmussen, H. B., Tosato, S., Rietschel, M., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.031 · Cited by 125 · see citing works

Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia

Ebdrup, B. H., Glenthoj, B. Y., Rasmussen, H., Aggernæs, B., Langkilde, A. R., Paulson, O. B., Lublin, H., Skimminge, A., & Baaré, W. F. C. (2010) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.090049 · Cited by 118 · see citing works

Prevalence of obesity in Canada

Bélanger-Ducharme, F., & Tremblay, A. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00179.x · Cited by 114 · see citing works

Impact of Obesity on Health‐related Quality of Life in Schizophrenia and Bipolar Disorder

Kolotkin, R. L., Corey‐Lisle, P. K., Crosby, R. D., Swanson, J. M., Tuomari, A. V., L'Italien, G. J., & Mitchell, J. E. (2008) · Obesity · doi:10.1038/oby.2007.133 · Cited by 110 · see citing works

Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems

Mukundan, A., Faulkner, G., Cohn, T. A., & Remington, G. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006629.pub2 · Cited by 103 · see citing works

Volumetric Abnormalities Predating the Onset of Schizophrenia and Affective Psychoses: An MRI Study in Subjects at Ultrahigh Risk of Psychosis

Dazzan, P., Soulsby, B., Mechelli, A., Wood, S. J., Velakoulis, D., Phillips, L., Yung, A. R., Chitnis, X. A., Lin, A. P., Murray, R. M., et al. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr035 · Cited by 103 · see citing works

Weight loss in overweight patients maintained on atypical antipsychotic agents

Centorrino, F., Wurtman, J. J., Duca, K., Fellman, V., Fogarty, K. V., Berry, J. M., Guay, D. M., Romeling, M., KIDWELL, J. E., Cincotta, S. L., et al. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803222 · Cited by 84 · see citing works

BMI and Neuronal Integrity in Healthy, Cognitively Normal Elderly: A Proton Magnetic Resonance Spectroscopy Study

Gazdzinski, S. P., Millin, R., Kaiser, L. G., Durazzo, T. C., Mueller, S. G., Weiner, M. W., & Meyerhoff, D. J. (2009) · Obesity · doi:10.1038/oby.2009.325 · Cited by 79 · see citing works

Psychological and quality of life changes in patients using GLP-1 analogues

Grant, P. S., LIPSCOMB, D. W., & Quin, J. (2011) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.03.002 · Cited by 75 · see citing works

Neuroimaging, Gut Peptides and Obesity: Novel Studies of the Neurobiology of Appetite

Gibson, C. D., Carnell, S., Ochner, C. N., & Geliebter, A. (2010) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2010.02025.x · Cited by 61 · see citing works

Efficacy of behavioural interventions in managing atypical antipsychotic weight gain

Gabriele, J. M., Dubbert, P. M., & Reeves, R. R. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00570.x · Cited by 58 · see citing works

Prevalence of liver disease in veterans with bipolar disorder or schizophrenia

Fuller, B. E., Rodriguez, V. L., Linke, A., Sikirica, M. V., Dirani, R. D., & Hauser, P. (2011) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.03.006 · Cited by 57 · see citing works

The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance

Lykkegaard, K., Larsen, P. J., Vrang, N., Bock, C., Bock, T. G., & Knudsen, L. B. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.05.011 · Cited by 52 · see citing works

Prevalence of obesity in Denmark

Due, P., Heitmann, B. L., & Sørensen, T. I. A. (2006) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00291.x · Cited by 46 · see citing works

What Can Imaging Reveal about Obesity and the Brain?

Jagust, W. J. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362146 · Cited by 43 · see citing works

Why Doesn’t the Brain Lose Weight, When Obese People Diet?

Peters, A., Bosy‐Westphal, A., Kubera, B., Langemann, D., Goele, K., Later, W., Heller, M., Hubold, C., & Müller, M. J. (2011) · Obesity Facts · doi:10.1159/000327676 · Cited by 29 · see citing works

In pursuit of neural risk factors for weight gain in humans

DelParigi, A., Pannacciulli, N., Le, D. S. N. T., & Tataranni, P. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.008 · Cited by 27 · see citing works

Bariatric Surgery: Indications, Safety and Efficacy

Ben‐David, K., & Rossidis, G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795656828 · Cited by 14 · see citing works

Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis

Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12 · see citing works

Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide

Astrup, A., Carraro, R., Finer, N., Harper, A., Kunešová, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., Rössner, S., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.203 · Cited by 9 · see citing works

Antipsychotics, mortality and schizophrenia: What are the facts?

Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.08.020 · Cited by 2 · see citing works

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial

Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250 · see citing works

Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis

Siskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13522 · Cited by 144 · see citing works

Effect of <scp>GLP</scp> ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: <scp>a</scp> randomized, placebo‐controlled trial

Ishøy, P. L., Knop, F. K., Broberg, B. V., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Glenthøj, B. Y., & Ebdrup, B. H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12795 · Cited by 102 · see citing works

The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children

Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99 · see citing works

The effects of antipsychotic medications on microbiome and weight gain in children and adolescents

Bretler, T., Weisberg, H., Koren, O., & Neuman, H. (2019) · BMC Medicine · doi:10.1186/s12916-019-1346-1 · Cited by 98 · see citing works

Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options

Verhaegen, A. A., & Gaal, L. F. V. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0719-6 · Cited by 68 · see citing works

One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients

Svensson, C. K., Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, C. T., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12982 · Cited by 66 · see citing works

GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats

Sharma, A. N., Ligade, S. S., Sharma, J. N., Shukla, P., Elased, K. M., & Lucot, J. B. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9591-7 · Cited by 66 · see citing works

Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review

Vasiliu, O. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12054 · Cited by 60 · see citing works

No cognitive‐enhancing effect of GLP ‐1 receptor agonism in antipsychotic‐treated, obese patients with schizophrenia

Ishøy, P. L., Fagerlund, B., Broberg, B. V., Bak, N., Knop, F. K., Glenthoj, B. Y., & Ebdrup, B. H. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12711 · Cited by 54 · see citing works

Drugs affecting body weight, body fat distribution, and metabolic function—mechanisms and possible therapeutic or preventive measures: an update.

Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53 · see citing works

Glucagon‐like peptide agonists for weight management in antipsychotic‐induced weight gain: A systematic review and meta‐analysis

Bak, M., Campforts, B. C. M., Domen, P. A. E., van Amelsvoort, T., & Drukker, M. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13734 · Cited by 52 · see citing works

Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes

Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49 · see citing works

Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism

Verhaegen, A. A., & Gaal, L. F. V. (2019) · Europe PMC (PubMed Central) · Cited by 38 · see citing works

Erratum: Effect of <scp>GLP</scp> ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: A randomized, placebo‐controlled trial

Ebdrup, B. H., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Knop, F. K., & Glenthøj, B. Y. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13204 · Cited by 35 · see citing works

Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis

Khaity, A. M., Al-dardery, N. M., Albakri, K. A., Abdelwahab, O. A., Hefnawy, M. T., Yousef, Y. S. A. H., Taha, R. E. W., Swed, S., Hafez, W., Hurlemann, R., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1153648 · Cited by 35 · see citing works

Impaired hormonal regulation of appetite in schizophrenia: A narrative review dissecting intrinsic mechanisms and the effects of antipsychotics

Lis, M., Stańczykiewicz, B., Liśkiewicz, P., & Misiak, B. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104744 · Cited by 33 · see citing works

Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes

Ishøy, P. L., Knop, F. K., Vilsbøll, T., Glenthoj, B. Y., & Ebdrup, B. H. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12101344 · Cited by 28 · see citing works

Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial

Ramsey, T. L., & Brennan, M. D. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.09.038 · Cited by 27 · see citing works

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Eriksson, R., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Knop, F. K., & Ebdrup, B. H. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00781 · Cited by 26 · see citing works

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol

Ishøy, P. L., Knop, F. K., Broberg, B. V., Baandrup, L., Fagerlund, B., Jørgensen, N. R., Andersen, U. B., Rostrup, E., Glenthoj, B. Y., & Ebdrup, B. H. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004158 · Cited by 24 · see citing works

Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-Treated Patients

Ebdrup, B. H., Knop, F. K., Madsen, A., Mortensen, H. B., Søgaard, B., Holst, J. J., Szecsi, P. B., & Lublin, H. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08820 · Cited by 21 · see citing works

Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats

Horská, K., Kučerová, J., Dražanová, E., Karpíšek, M., Demlová, R., Kašpárek, T., & Kotolová, H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.003 · Cited by 20 · see citing works

A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults

Patino, L. R., Strawn, J. R., Adler, C. M., Blom, T. J., Welge, J. A., & DelBello, M. P. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.046 · Cited by 18 · see citing works

Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study

Campforts, B. C. M., Drukker, M., van Amelsvoort, T., & Bak, M. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06317-7 · Cited by 17 · see citing works

Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness

Kouidrat, Y., Amad, A., & Binder, M. D. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150619093128 · Cited by 14 · see citing works

Genetic Variation in the GCG and in the GLP1R Genes and Antipsychotic-Induced Weight Gain

Brandl, E. J., Tiwari, A. K., Chowdhury, N. I., Zai, C. C. H., Lieberman, J. A., Meltzer, H. Y., Kennedy, J. L., & Müller, D. J. (2014) · Pharmacogenomics · doi:10.2217/pgs.13.247 · Cited by 12 · see citing works

GLP-1 agonists for metabolic disorders in schizophrenia

Kouidrat, Y., & Amad, A. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.09.019 · Cited by 8 · see citing works

Glucagon-like peptide-1 receptor agonists as an effective therapeutic agent for diabetes mellitus and obesity in patients with schizophrenia under treatment with second-generation antipsychotics

Ando, T., Hatada, K., Sata, M., Tachiki, H., Fukazawa, T., Kusumoto, S., Horie, I., Abiru, N., Matsumoto, S., & Kawakami, A. (2018) · Nagasaki University's Academic Output SITE (Nagasaki University) · doi:10.11343/amn.61.151 · Cited by 4 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on anthropometric and adiposity measures in patients with antipsychotic-induced weight gain: A systematic review and meta-analysis

Lee, S., Kim, M., Trott, M., Siskind, D. J., & Kim, J. H. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456190 · Cited by 2 · see citing works

Risperidone But Not Quetiapine Treatment Is Associated With Increased Appetite But Not Satiety Hormones in Children During An Oral Glucose Tolerance Test

Ngai, Y. F., Devlin, A. M., & Panagiotopoulos, C. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000956 · Cited by 2 · see citing works

Drug‑induced weight gain: pathophysiological mechanisms, clinically relevant drug classes, and management strategies

Skobeleva, T. N., Savgacheva, M. Y., & Karakchiev, D. A. (2026) · Patient-Oriented Medicine and Pharmacy · doi:10.37489/2949-1924-0139

Semaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia

Abbas, N., Memon, A. A., Zulfiqar, R., Noon, A. Z., Shah, S. M. A., Panhwar, K., Sadia, Z., Khan, M. S., Akbar, M. B., Iftikhar, S., et al. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002234

Efficacy and safety of semaglutide versus placebo for people with schizophrenia spectrum disorders with obesity or early-stage metabolic abnormalities: A systematic review and meta-analysis of randomized controlled studies

Rasul, M., Hassan, A., Rehman, U. U., Sarmad, M., Farooq, A. S., Khalil, H., Jahangir, M. A., Abideen, Z. U., Bashir, M. K., Cheema, U., et al. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261473919

GLP-1 receptor agonists and weight loss in schizophrenia – past, present, and future

Trott, M., Arnautovska, U., & Siskind, D. J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000952 · Cited by 22 · see citing works

Effect of <scp>GLP</scp> ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: <scp>a</scp> randomized, placebo‐controlled trial

Ishøy, P. L., Knop, F. K., Broberg, B. V., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Glenthøj, B. Y., & Ebdrup, B. H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12795 · Cited by 102 · see citing works

Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis

Siskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13522 · Cited by 144 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis

Sobral, M. V. S., Menechini, R. B., da Silva, J. B. C., de Vasconcelos, A. V., Graciolli, L. H. M. D. S. G., Maciel, R. C., Monteiro, A., Amador, W. F. O., & Acuia, T. A. D. S. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.06.025 · Cited by 1 · see citing works

Use of GLP-1 Analogues in Patients with Schizophrenia and Other Neuropsychiatric Disorders: A Literature Review

Pernal, M., Roguska, Z., Poniewozik, P., Grabowski, K., Dziuba, N., Sim, A., Mioduszewska, J., Rot, P., Poniewozik, P., & Zuzak, A. P. (2026) · Quality in Sport · doi:10.12775/qs.2026.54.70410